trending Market Intelligence /marketintelligence/en/news-insights/trending/Z2Z7YjLE34LkhJ9PL8bAaA2 content esgSubNav
In This List

Gelesis secures $84M to commercialize weight management drug Plenity

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Gelesis secures $84M to commercialize weight management drug Plenity

Gelesis Inc. secured over $84 million by selling shares worth $63.4 million and receiving $21.2 million in grants and loans.

Private equity firm Vitruvian Partners LLP was the largest investor in the equity trade.

Gelesis intends to use the capital secured to commercialize its FDA-approved weight management drug Plenity, which works by absorbing water in the stomach and mixing it with food to make a meal feel more filling.

Gelesis has obtained nearly $100 million this year to support the U.S. launch of Plenity, the company said in a statement.